The Oklahoma Heart Institute Team will conduct a comprehensive evaluation to determine whether this procedure is an appropriate therapeutic option. In certain cases, TAVR may not be an option because of co-existing medical conditions or disease processes that would prevent the patient from experiencing the expected treatment benefit or because the risks outweigh the benefits. For those who are candidates for TAVR, this therapy may improve survival (make you live longer) and provide relief from the often debilitating symptoms associated with severe aortic stenosis.
The current ACC/AHA Guidelines for the Management of Patients with Valvular Heart Disease recommend surgical aortic valve replacement (SAVR) for virtually all patients with severe, symptomatic aortic stenosis. Without replacement of the aortic valve, this disease is life-threatening and previous studies have shown that 50% of patients will not survive more than an average of two years after the onset of symptoms. While open-heart aortic valve replacement surgery is the gold standard treatment for severe symptomatic native aortic valve stenosis, there are patients who are not candidates for open-chest surgery. These inoperable patients may be unable to undergo traditional surgery because of factors such as age, history of heart disease, frailty or other health issues. For these patients, TAVR may be an option.